论文部分内容阅读
目的:探讨小剂量重组人粒细胞巨噬细胞集落刺激因子(rhGM-CSF)化疗前应用在减轻骨髓抑制、缩短住院时间、减少医疗费用方面的作用。方法:实验组化疗前48小时GM-CSF300μg皮下注射1次,出现骨髓抑制后实验组与对照组均给予rhGM-CSF300μg皮下注,1次/日,直至WBC≥4.0×109/L。结果:实验组的白细胞减少、粒细胞减少及血小板下降均较对照组轻,(P<0.05),实验组白细胞恢复时间短于对照组,(P<0.05),住院天数及药费也存在显著性差异(P<0.05)。结论:化疗前给予rhGM-CSF,可以有效地降低骨髓抑制的发生率及发生程度,缩短骨髓恢复时间,在降低医疗费用、加快床位周转、提高病床使用率方面也显示出一定的优势。
Objective: To investigate the effect of low-dose recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) before chemotherapy in reducing myelosuppression, shortening hospital stay and reducing medical costs. Methods: The experimental group was injected subcutaneously with 300μg of GM-CSF 300μg 48 hours before the chemotherapy, and rhGM-CSF 300μg was injected subcutaneously once a day until WBC≥4.0 × 109 / L after the bone marrow suppression. Results: The leukopenia, neutropenia and thrombocytopenia in the experimental group were lighter than those in the control group (P <0.05). The leukocyte recovery time in the experimental group was shorter than that in the control group (P <0.05) Sex differences (P <0.05). Conclusion: The rhGM-CSF administered before chemotherapy can effectively reduce the incidence and occurrence of bone marrow suppression and shorten the recovery time of bone marrow, and also shows some advantages in reducing medical expenses, accelerating the turnover of bed spaces and improving the utilization of hospital beds.